Somewhat Positive Media Coverage Somewhat Unlikely to Impact Nevro (NVRO) Share Price

Media headlines about Nevro (NYSE:NVRO) have trended somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nevro earned a news impact score of 0.12 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 47.0546165822618 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

Nevro (NYSE NVRO) opened at $66.41 on Friday. The company has a quick ratio of 6.81, a current ratio of 8.78 and a debt-to-equity ratio of 0.59. Nevro has a 1 year low of $65.40 and a 1 year high of $99.63.

Nevro (NYSE:NVRO) last posted its quarterly earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02. Nevro had a negative return on equity of 17.27% and a negative net margin of 14.09%. The business had revenue of $82.26 million for the quarter, compared to analyst estimates of $80.50 million. During the same period last year, the company earned ($0.14) EPS. Nevro’s revenue for the quarter was up 35.0% compared to the same quarter last year. analysts predict that Nevro will post -1.27 earnings per share for the current year.

A number of equities analysts recently weighed in on NVRO shares. Zacks Investment Research raised Nevro from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th. BidaskClub cut Nevro from a “hold” rating to a “sell” rating in a report on Saturday, October 28th. TheStreet raised Nevro from a “d+” rating to a “c-” rating in a report on Monday, November 6th. Canaccord Genuity decreased their price objective on Nevro from $120.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. Finally, Leerink Swann reissued an “outperform” rating and set a $110.00 price objective (up from $105.00) on shares of Nevro in a report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. Nevro presently has a consensus rating of “Hold” and a consensus price target of $100.00.

In related news, CFO Andrew H. Galligan sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $75.11, for a total transaction of $525,770.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael F. Demane sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $87.73, for a total value of $2,193,250.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 63,467 shares of company stock worth $5,576,679. 12.10% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/10/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-nevro-nvro-share-price.html.

About Nevro

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Insider Buying and Selling by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply